Is the FDA Delay Actually Good News for Biogen's Alzheimer's Drug?

The Food and Drug Administration (FDA) recently extended its timeframe to approve or reject Biogen (NASDAQ: BIIB) and Eisai's (OTC: ESALY) Alzheimer's disease drug aducanumab by three months to June 7, 2021. In this video from Motley Fool Live, recorded on Feb. 1, Fool.com contributors Brian Orelli and Keith Speights discuss how the delay could actually be good news for the companies.

Continue reading

Source Fool.com